C. Giovanni Traverso, MB, BChir, PhD is an Assistant Professor of Medicine at Harvard Medical School, and a Gastroenterologist in the Division of Gastroenterology at Brigham and Women’s Hospital.
Dr. Traverso received his medical degrees from the University of Cambridge and completed his Internal Medicine residency training at the Brigham and Women’s Hospital (BWH). He subsequently completed his fellowship in Gastroenterology at Massachusetts General Hospital (MGH) and joined the faculty of the MGH in 2014. He transitioned back to BWH in 2016.
Dr. Traverso completed his PhD thesis on novel technologies for the non-invasive detection of colorectal cancer from fecal DNA in the laboratory of Professor Bert Vogelstein at Johns Hopkins University. For his post-doctoral research he transitioned to the fields of chemical and biomedical engineering in the laboratory of Professor Robert Langer at the Massachusetts Institute of Technology (MIT) where he developed a series of novel technologies for drug delivery as well as physiological sensing via the gastrointestinal tract.
His current research program is focused on developing the next generation of drug delivery systems to enable efficient delivery of therapeutics through the gastrointestinal tract.
RESEARCH PROGRAM
Dr. Traverso’s research program is focused on developing novel technologies for drug delivery through the gastrointestinal (GI) tract. His work aims to enable a broader spectrum of therapeutics to be delivered through the GI tract, to extend the duration of drug release after a single administration event, as well as to enhance precision in localization of drug delivery, to maximize drug delivery to areas of disease while minimizing side effects from drugs in non-diseased tissues. The overall goal of Dr. Traverso’s research is to develop innovative technologies to advance the delivery of therapeutics in order to help patients receive treatment through the most facile, effective and targeted means possible.
Dr. Traverso also has a long-standing research interest in the molecular underpinnings of cancer, and how understanding these can be leveraged for early detection and treatment.